gip and glp-1 agonist & Agonists | Obesity Diabetes Management | Harrison's updates (22nd Ed.) The Landscape Of GLP-1 Receptor

Description

doi: 10.1002/14651858.CD006739.pub2

Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus

Ethics declarations Conflict of interest Julia Herrou, Guillaume Mabilleau, Jean-Michel Lecerf, Thierry Thomas, Emmanuel Biver and Julien Paccou declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

GLP-1 agonists excel at weight reduction and cardiovascular protection, while SGLT2 inhibitors lead in renal preservation and heart failure management

Regular follow-up with healthcare providers, including A1c testing approximately 3 months after discontinuation for patients with diabetes, is recommended